Pet Pharm Biotech Co., Ltd. (TPEX:7762)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
49.45
-5.35 (-9.76%)
At close: Mar 27, 2026

Pet Pharm Biotech Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
24.9914.519.15-3.81
Depreciation & Amortization
34.5818.2816.6714.3
Other Amortization
-1.330.08-
Loss (Gain) From Sale of Assets
---0.21
Asset Writedown & Restructuring Costs
---0.1
Stock-Based Compensation
0.620.020.01-
Provision & Write-off of Bad Debts
0.02-0.03-1.21.2
Other Operating Activities
-0.91-2.32--
Change in Accounts Receivable
-19.02-2.51-9.13-8.53
Change in Inventory
0.97-2.88-4.99-1.33
Change in Accounts Payable
-13.673.111.9-11.89
Change in Unearned Revenue
0.510.370.85-0.24
Change in Other Net Operating Assets
6.21-0.977.43-7.83
Operating Cash Flow
34.328.8820.75-17.83
Operating Cash Flow Growth
18.75%39.16%--
Capital Expenditures
-29.51-188.4-12.68-10.04
Sale of Property, Plant & Equipment
---1.5
Cash Acquisitions
-107.11---
Sale (Purchase) of Intangibles
-0.37-1.08--
Investment in Securities
-44-65-91-50
Other Investing Activities
-220.63-8.46-30.10.48
Investing Cash Flow
-401.61-262.93-133.77-58.07
Long-Term Debt Issued
1.58100--
Short-Term Debt Repaid
----4.05
Long-Term Debt Repaid
-109.38-7.03-5.25-3.78
Total Debt Repaid
-109.38-7.03-5.25-7.82
Net Debt Issued (Repaid)
-107.892.97-5.25-7.82
Issuance of Common Stock
567.03162.4227096.5
Common Dividends Paid
-5.05-8.04--
Other Financing Activities
0.01---
Financing Cash Flow
454.18247.35264.7588.68
Net Cash Flow
86.8713.3151.7312.78
Free Cash Flow
4.79-159.518.08-27.87
Free Cash Flow Margin
2.16%-122.05%6.85%-36.80%
Free Cash Flow Per Share
0.09-3.910.27-1.16
Cash Interest Paid
-0.180.180.2
Cash Income Tax Paid
-0.1--
Levered Free Cash Flow
-46.97-231.23-84.79-
Unlevered Free Cash Flow
-46.41-231.12-84.69-
Change in Working Capital
-25-2.89-3.95-29.82
Source: S&P Global Market Intelligence. Standard template. Financial Sources.